Oxaliplatin, /m2

Phase 3Small molecule

Roche

Oxaliplatin, /m2 is one of 65 small molecule programs targeting Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

94 2

Braftovi

Pfizer

Phase 3

11 3

Lenvima

Eisai

Phase 3

1 4

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 5

Alinia

RRomark Laboratories L.C.

Phase 3

1 6

Cecon

MMcGuff Pharmaceuticals, Inc.

Phase 3

1 7

Vatalanib

Novartis

Phase 3

2 8

Investigator's Choice Chemotherapy

Genmab

Phase 3

1 9

HX008

BBinhui Biopharmaceutical Co., Ltd.

Phase 3

1 10

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Rectal Cancer Patients

NCT04246684

Clinical

Trials by Indication[1]

Rectal Cancer Patients1 trial

Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting·PProf. Dr. med. Claus Rödel·Phase 3·NCT04246684·702 enrolled

Adenocarcinoma1 trial

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Completed·—·Phase 2·NCT03283761·39 enrolled

Metastatic Colorectal Cancer1 trial

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 3·NCT00069095·2,035 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Oxaliplatin, /m2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxaliplatin, /m2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxaliplatin, /m2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Oxaliplatin, /m2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Rectal Cancer Patients1 trial

Adenocarcinoma1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News